Authors: Alice Weatherston
The first completed Phase III trial of a tau-targeting Alzheimer’s disease drug has revealed varying results but marks a potential milestone in drug development of disease-modifying treatments for this currently uncurable condition. The outcomes, which were presented at the Alzheimer’s Association International Conference 2016 (22 – 28th July 2016, ON, Canada) received diverse reactions across the media and in the scientific community.
The drug, termed leuco-methylthioninium-bis(hydromethanesulfonate) or LMTM, was developed by TauRx Therapeutics (Aberdeen, UK) for the treatment of mild to moderate Alzheimer’s disease. The compound is a selective tau aggregation inhibitor.